Pricing Log in Create free account

Maze Therapeutics, Inc. (MAZE) vs Replimune Group, Inc. (REPL)

Maze Therapeutics, Inc. and Replimune Group, Inc. are both Biotechnology companies. Maze Therapeutics, Inc. and Replimune Group, Inc. are of similar size ($1.9B and $1.8B). Across the 10 metrics below, Maze Therapeutics, Inc. leads on 8 and Replimune Group, Inc. on 2.

Valuation

Metric MAZE REPL Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 4.46 11.16 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (7.36%) (12.86%) (32.88%)
Free cash flow yield (5.29%) (10.75%) (23.13%)

Profitability

Metric MAZE REPL Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (37.35%) (115.80%) (51.96%)
Return on assets (31.99%) (71.01%) (46.06%)
Return on invested capital (112.36%) (928.27%) 0.00%

Growth

Metric MAZE REPL Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (344.00%) (10.10%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MAZE REPL Biotechnology median
Debt to equity 0.09 0.59 0.00
Current ratio 18.31 7.11 4.97
Net debt to EBITDA 2.43 0.51 1.01

Dividend

Metric MAZE REPL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MAZE REPL Biotechnology median
Market cap 1.81b 1.90b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack